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2.01, 95% CI 1.22–3.33), and concomitant stroke (HR 1.86, 
95% CI 1.29–2.67) have an unfavorable impact on patient 
survival. Gender, disease extent, mucosal involvement, and 
indirect immunofluorescence result were not shown to be 
linked to mortality by our analysis. This study indicated 
that BP patients with older age, circulating antibodies, 
dementia, and stroke are at greater risk of mortality. Cli-
nicians should be aware of this association and utilize this 
information in patient education and treatment process.
Keywords Bullous pemphigoid · Autoimmune blistering 
disease · Prognosis · Mortality · Survival
Introduction
Bullous pemphigoid (BP) is a chronic debilitating auto-
immune blistering disease which has a high mortality and 
morbidity [28]. BP mainly affects the elderly people, caus-
ing symptoms, such as widespread tense blistering and 
itching. Previous studies reported an incidence of BP rang-
ing from 2.5 to 42.8 cases per million per year [2, 11, 14, 
23]. BP has been reported to be significantly associated 
with mortality, with morality rates ranging from 6 to 41% 
within the first year after diagnosis [1, 3–6, 12, 15, 22, 27, 
29, 30, 32]. BP patients also have increased mortality com-
pared with their age and sex-matched controls in the gen-
eral population [2–4, 12, 14].
However, relatively few studies have investigated prog-
nostic factors of BP mortality, with considerably vari-
ous results. Old age has been shown to be related to poor 
outcome in BP in several studies [6, 12, 15, 27], but there 
are conflicting results on whether old age is an independ-
ent risk factor for mortality in BP [3, 21, 22]. In addition, 
poor general condition and low karnofsky scale [26] have 
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often been associated with increased mortality [1, 15, 21, 
29]. Interestingly, factor directly related to BP, such as the 
severity and extent of skin lesion, does not often predict 
survival [3, 12, 21, 22].
In addition, BP patients have complex comorbidity pro-
files, most notably neurological disorders as well as auto-
immune, infectious and cardiovascular disorders [28]. Vari-
ous studies have confirmed a strong association between 
BP and neurological diseases, particularly dementia, 
stroke, Parkinson disease, multiple sclerosis, and epilepsy 
[20]. BP is associated with development of autoantibod-
ies directed against the hemidesmosomal BP autoantigens 
BPAG1 and BPAG2. BPAG1 has two isoforms: BPAG1-e 
is mainly expressed in skin, while BPAG1-a is expressed in 
central nervous system [20]. It is commonly suggested that 
an immunological cross-reaction between these isoforms 
could be the pathogenic reason. However, the prognostic 
value of co-existing neurological disorders as well as other 
comorbidities for BP mortality is unclear.
In addition, the sample sizes of these studies are often 
relatively small, leading to limited statistical power to 
detect true associations. In addition, there is still no sys-
tematic and quantitative assessment of published findings 
on this topic. We, therefore, conducted a meta-analysis 
to quantitatively assess the association between several 
potential prognostic factors and risk of mortality in bullous 
pemphigoid.
Materials and methods
This meta-analysis was conducted according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement protocol [25].
Search strategy and study selection
We performed an exhaustive search on Pubmed (from 
1978 to November 2016), Embase (from 1974 to Novem-
ber 2016) and Cochrane Library (from 1994 to November 
2016) to identify articles that studied the prognostic factors 
for BP mortality. There was no limit on human race, geo-
graphic region, language, or publication type. The major 
terms used included: “bullous pemphigoid”, “mortality”, 
“fatality”, “survival”, “death”, “prognosis”, and “prognos-
tic”. The following selection criteria were performed on 
Pubmed as an example:
1. bullous pemphigoid [Title] or bullous pemphigoid 
[Mesh Terms];
2. mortality or fatality or survival or death or prognosis or 
prognostic [All Fields];
3. 1 and 2.
Studies eligible for inclusion in this meta-analysis met 
the following criteria: (a) cohort study design; (b) meas-
ure potential prognostic factors for BP mortality; (c) pro-
vide sufficient data for calculating the effect size with 95% 
confidence intervals (CIs); and (d) when the same author’s 
data obtained from the same or overlapping patients in 
more than one publication, only the most recent report or 
the most complete one was selected in the analysis. We 
excluded case reports, reviews, meta-analyses, and letters. 
Studies investigating remission or relapse but not mortality 
of BP were excluded. Childhood bullous pemphigoid was 
not considered in the present study. Additional studies were 
identified by a manual search of the references of original 
studies. The literature search and inclusion of eligible arti-
cles was performed independently by two authors (Liu YD 
and Zhao WL) and disagreements were resolved at each 
step by consensus.
Data extraction
All data were extracted independently and crosschecked by 
two authors (Liu YD and Zhao WL). Data retrieved from 
the studies included authors, year of publication, patient 
source, number of patients included in the study, study 
type, follow-up time, and statistical results regarding the 
influence of prognostic factors on the risk of mortality. If 
both 1 year mortality and overall mortality were reported in 
a study, 1 year mortality was extracted for analysis.
Quality assessment
Quality assessment of each study was performed indepen-
dently by the two authors (Liu YD and Zhao WL), using 
the Newcastle–Ottawa Scale (NOS) (http://www.ohri.ca/
programs/clinical_epidemiology/oxford.asp), which graded 
studies according to the quality of selection, comparability, 
and outcome of study participants. Studies that achieved 
seven or more stars on NOS were considered to be of high 
quality, four to six stars were medium quality, and fewer 
than four stars were poor quality [24]. Discrepancies were 
addressed by re-evaluation of the original article and dis-
cussion with a third author (Wang YH).
Statistical methods
For the quantitative aggregation of the survival results, we 
reported summary measures of effect size using a pooled 
hazard ratio (HR) with 95% confidence interval. If avail-
able, we extracted the risk estimates that underwent mul-
tivariate adjustment. For studies in which the HR corre-
sponding to the 95% CI was not given directly, published 
data from original papers were used to calculate the HR 
according to the methods described previously [31]. In a 
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few situations where there was not sufficient information 
for HR estimation, we calculated the relative risk (RR) with 
95% CI as a crude substitution of HR. Study heterogene-
ity was assessed using the Cochran Q test with P value for 
significance set at 0.10 and the I2 statistic with values of 25, 
50 and 75% considered as low, moderate, and high hetero-
geneity, respectively [13]. To estimate the pooled HR, ran-
dom-effects model of DerSimonian and Laird was used [7]. 
Publication bias was evaluated with funnel plot and Egger’s 
test (P < 0.05 was considered statistically significant) [9]. 
The statistical analysis was performed by the STATA 14.0 
software (StataCorp, College Station, TX, USA).
Results
Study characteristics
The preliminary literature search returned 660 studies 
matching the initial search criteria, as shown in Fig.  1. 
After screening, we identified 14 studies on ten Caucasian 
and four Asian population samples, including a total of 
2499 patients after extracting overlapping patients between 
studies. The major characteristics of the 14 eligible publi-
cations were reported in Table  1. Of the 14 studies, nine 
were retrospective cohort studies, and five were prospective 
cohort studies. Based on NOS, 13 studies were considered 
to be of high quality and one was of medium quality, as 
shown in Table  2. Most studies were conducted in major 
centers with an exception of one Swiss study which was 
population-based [6]. When there was identical or overlap-
ping patient population between the 14 studies, we only 
included the study with the more complete population in 
the investigation of a specific prognostic factor of interest 
[1, 15, 16, 29].
Quantitative synthesis
Age
To investigate the effect of age on survival, we included the 
ten studies which compared survival outcome on elderly 
BP patients with younger age patient populations. In most 
studies, patients’ median or mean age at the time of diag-
nosis was used as the cut-off value to categorize young 
and elderly patients, and the cut-off value ranged from 67 
to 83  years across studies. The pooled HR of old age for 
mortality risk was 1.63 (95% CI 1.34–1.97, P < 0.001). Sig-
nificant heterogeneity was seen among studies (I2 = 86.6%, 
P < 0.001). In subgroup analysis by age cut-off value, stud-
ies using cut-off age ≥80 (HR 1.42; 95% CI 1.16–1.73) and 
studies using cut-off age <80 (HR 2.14; 95% CI 1.32–3.44) 
both showed statistical significance. Study heterogeneity 
remained moderate to high for studies using cut-off age ≥80 
(I2 = 90.4%, P < 0.001) and studies using cut-off age <80 
(I2 = 55.2%, P = 0.063). Visual inspection of the funnel plot 
suggested obvious asymmetry, and this was further sup-
ported by Egger’s test showing evidence for reporting bias 
(P = 0.001). “Trim and fill” method showed that five stud-
ies had to be added to correct funnel plot asymmetry, and 
Fig. 1  Flowchart of studies 
included in the meta-analysis
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the pooled outcome was no longer statistically significant 
(HR 1.17; 95% CI 0.96–1.42, P = 0.130). Figures 2, 3, 4, 5, 
6, 7, 8, 9 show the forest plots with summary measures of 
the associations between BP mortality and potential prog-
nostic factors. Figure 10 illustrates the funnel plots of com-
ponent studies in this meta-analysis. Table  3 summarizes 
the pooled results of potential risk predictors.
Gender
No significant impact was observed for BP mortality, 
and the pooled HR of male vs female was 1.01 (95% CI 
0.81–1.25, P = 0.944), as shown in Fig.  3. Low-to-mod-
erate heterogeneity was observed between the studies 
(I2 = 41.6%, P = 0.072). Visual inspection of the funnel plot 
did not reveal obvious asymmetry (Fig. 10), and it was con-
firmed by Egger’s test (P = 0.706).
Extensive disease
The definition of disease extent varied among studies. Joly 
et  al. have defined extensive disease as the occurrence of 
more than ten new blisters per day [16, 17]. Two studies 
graded BP disease severity based on the percentage of 
body surface area involvement as follows: mild, <10%; 
moderate, 10–30%; and severe, >30% [21, 27]. Four stud-
ies defined localized disease as isolated lesions in one ana-
tomical region, and generalized disease for patients with 
moderate-to-diffuse lesions in two or more regions [3, 12, 
22, 29]. For simplicity, we combined these eight studies 
and the pooled HR of extensive disease was 1.19 (95% CI 
0.97–1.46, P = 0.102), as shown in Fig. 4. No heterogeneity 
was observed between the studies (I2 = 16.2%, P = 0.302). 
Visual inspection of the funnel plot could not rule out pub-
lication bias (Fig. 10), but the result of Egger’s test was not 
significant (P = 0.233).
Mucosal lesion
The pooled HR of mucosal lesion vs no mucosal lesion was 
1.00 (95% CI 0.65–1.56, P = 0.992), as illustrated in Fig. 5. 
The heterogeneity between the studies was low (I2 = 34.5%, 
P = 0.205). The funnel plot showed a lack of small size 
studies with positive association, suggesting probable pub-
lication bias (Fig. 10). Egger’s test, however, failed to pro-
vide any evidence for small study effect (P = 0.079).
Circulating BP autoantibody
Because only six studies investigated the relationship 
between the presence of circulating BP antibodies and 
patient survival, we pooled the results of all these studies 
together, regardless of the detection method of antibodies. 
When a study performed both indirect immunofluorescence 
(IIF) and enzyme-linked immunosorbent assay (ELISA) 
or immunoblot, we utilized survival data based on ELISA 
(preferentially anti-BP180) or immunoblot instead of IIF, 
since ELISA result was reported to indicate disease activ-
ity [10]. The presence of circulating antibodies conferred a 
1.77 fold increased risk (95% CI 1.20–2.62, P = 0.004), as 
shown in Fig. 6. The studies were considered homogenous 
(I2 = 0.0%, P = 0.632). The funnel plot was roughly sym-
metrical (Fig.  10). Egger’s test also failed to provide any 
evidence for small study effect (P = 0.859). In addition, we 
performed analysis for survival results based on positive 
IIF (HR = 1.17; 95% CI 0.75–1.81, P = 0.488), as shown in 
Table 1  Main characteristics of the eligible studies
a Follow up time in median follow up time
First author Year Country Sample size Study type Type of care setting HR estimation Follow up time Study quality
Lee 2014 Korea 168 Retrospective Tertiary center 1-year mortality 2.19  yearsa 8
Cai 2014 Singapore 359 Retrospective Tertiary center Overall mortality 3 years 8
Gual 2014 Spain 101 Retrospective Tertiary center 1-year mortality 1 year 9
Li 2013 China 140 Retrospective Inpatient Overall mortality 3 yearsa 8
Zhang 2013 China 94 Retrospective Inpatient 1-year mortality 1 year 9
Cortés 2012 Switzerland 60 Retrospective Inpatient Overall mortality 1 to 5 years 8
Cortés 2011 Switzerland 115 Prospective Outpatient Overall mortality 3 years 9
Joly 2009 France 312 Prospective Tertiary center 1-year mortality 1 year 9
Parker 2008 USA 223 Retrospective Outpatient and Inpatient Overall mortality 2.69  yearsa 6
Joly 2005 France 170 Prospective Tertiary center 1-year mortality 1 year 9
Rzany 2002 Germany 369 Retrospective Inpatient 1-year mortality 1.9  yearsa 9
Joly 2002 France 341 Prospective Tertiary center 1-year mortality 1 year 9
Roujeau 1998 France 217 Retrospective Tertiary center 6 month mortality 1.5  yeara 8
Bernard 1997 France 94 Prospective Tertiary center 1-year mortality 1 year 7
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Fig. 7. The funnel plot was roughly symmetrical (Fig. 10), 
and Egger’s test was not significant (P = 0.622).
Dementia
Patients with dementia (including Alzheimer’s dementia 
and all other types of dementia) were twice more likely to 
die than patients who did not have dementia. The pooled 
HR was 2.01 (95% CI 1.22–3.33, P = 0.006), as shown in 
Fig. 8. There was moderate-to-high heterogeneity between 
the studies (I2 = 64.6%, P = 0.015). The funnel plot was not 
perfectly symmetrical (Fig. 10), suggesting possible publi-
cation bias. Egger’s test, however, failed to provide any evi-
dence for small study effect (P = 0.853).
Stroke
Patients with stroke had nearly two-fold increased risk 
of death compared with patients who did not have this 
comorbidity. The pooled HR was 1.86 (95% CI 1.29–2.67, 
P < 0.001), as illustrated in Fig.  9. There was low-to-
moderate heterogeneity between the studies (I2 = 40.8%, 
P = 0.133). Visual inspection of the funnel plot suggested 
probable reporting bias (Fig. 10), although Egger’s test did 
not provide any evidence for small study effect (P = 0.277).
Discussion
In this meta-analysis of 14 studies that included 2499 sub-
jects, we found that older age, presence of circulating anti-
bodies regardless of detection method, co-existing demen-
tia, and stroke were associated with an increased risk of 
BP mortality. No significant association was observed for 
gender, disease extent, mucosal involvement, or IIF result 
and survival.
In consistence with most studies included in the cur-
rent analysis, we found no survival difference based on sex. 
However, age at diagnosis was associated with increased 
risk of death, with advanced age being a poor prognostic 
factor. Stratification of studies based on age cut-off value 
demonstrated that the effect size was more significant when 
the cutoff was lower, suggesting that the truly younger 
patients may have a better prognosis. Discrepancies in the 
age cut-off values, patient baseline characteristics, and 
treatment approaches between studies might contribute to 
the high level of heterogeneity. The pooled result did not 
remain comparable after “trim and fill” adjustment, sug-
gesting that publication bias might have led to an overesti-
mation of the effect of age on survival. However, the asym-
metry in funnel plot may also simply be the play of chance, 
since only ten studies were included, or true heterogene-
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Fig. 2  Forest plots: association between bullous pemphigoid mortality and old age
Fig. 3  Forest plots: association between bullous pemphigoid mortality and gender
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two outlier investigations by Roujeau et al. [29] and Cortés 
et al. [5] were small studies with less than 100 participants. 
Nevertheless, the above finding indicates that younger age 
at the diagnosis of BP does not necessarily denote a lower 
risk of mortality, and physicians should be more cautious 
about patients’ general health condition and comorbidity 
profile.
As reported previously, more extensive form of BP did 
not significantly increase the risk on mortality. Although 
the extent and distribution of disease are a variable 
Fig. 4  Forest plots: association between bullous pemphigoid mortality and extensive disease
Fig. 5  Forest plots: association between bullous pemphigoid mortality and mucosal lesion
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susceptible to high variability between centers and may 
introduce information bias, especially in retrospective stud-
ies, heterogeneity between the included studies was low. 
The presence of mucosal lesion was also not predictive of 
poor survival outcome in our analysis. Of the other factors 
related to BP activity that were not included in this meta-
analysis due to insufficient data for statistical pooling, such 
as pruritus [15, 29] and eosinophilia [1, 15, 22, 29], no 
mortality difference was found by previous investigations. 
These findings suggest that inherent factors such as age and 
Fig. 6  Forest plots: association between bullous pemphigoid mortality and circulating BP autoantibody
Fig. 7  Forest plots: association between bullous pemphigoid mortality and positive IIF
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gender, as well as disease severity at the time of diagnosis, 
may not influence mortality as much as general condition 
and concomitant morbidities.
Our analysis corroborated previous finding that IIF 
is not a sensitive indicator of BP clinical activity [18], 
but suggested that the presence of circulating antibodies 
regardless of detection method increased mortality risk, 
pointing to a predictive role of ELISA test. Unfortunately, 
since only three studies investigated survival progno-
sis based on ELISA result, we did not perform statistical 
Fig. 8  Forest plots: association between bullous pemphigoid mortality and dementia
Fig. 9  Forest plots: association between bullous pemphigoid mortality and stroke
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pooling for this. To date, IIF plays a key role in the detec-
tion of circulating antibodies and is often used as the rou-
tine test. However, the circulating autoantibodies can also 
be detected by more accurate serological assays, includ-
ing immunoblotting and ELISA [18]. Of note, ELISA has 
been demonstrated as a useful tool to detect circulating 
antibodies in BP with its high sensitivity and specificity, 
particularly to recombinant BP180 antigen [18]. Moreover, 
it has the ability to reflect the severity of bullous pemphi-
goid, presumably because autoantibody against BP180 is 
believed to be pathogenic in BP [10]. It is noteworthy that 
this represents an intrinsic risk factor that correlates with 
BP mortality.
Severe concomitant morbidities at the time of diag-
nosis of bullous pemphigoid, such as neurological dis-
orders, cardiac insufficiency, diabetes, and malignancies, 
increase the risk of mortality [3, 12, 21]. Interestingly, 
there is a strong link between BP and neurological dis-
eases. In this study, we evaluated the impact of two most 
common neurological diseases in BP patients, dementia, 
and stroke, on the survival of BP patients. Our pooled 
data indicated a roughly two-fold higher mortality risk 
for BP patients with dementia or stroke. The exact mech-
anism underlying the link between neurological diseases 
and BP has not yet been fully elucidated, but a putative 
autoimmune reaction against BP antigens in the brain, 
Fig. 10  Funnel plots of studies evaluating the relationship between bullous pemphigoid mortality and potential prognostic factors a old age, b 
gender (male vs female), c extensive disease, d mucosal lesion, e circulating autoantibody, f positive IIF, g dementia, h stroke
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Fig. 10  (continued)
Table 3  Summary of pooled 
results of potential prognostic 
factors
S significant, NS non-significant, IIF indirect immunofluorescence
Prognostic factor Number of 
studies
Participants Hazard ratio (95% CI) Statistical difference
Old age 10 1922 1.63 (1.34–1.97) S (P < 0.001)
Gender (male vs female) 11 2016 1.01 (0.81–1.25) NS (P = 0.944)
Extensive disease 8 1861 1.19 (0.97–1.46) NS (P = 0.102)
Mucosal lesion 4 962 1.00 (0.65–1.56) NS (P = 0.992)
Circulating autoantibody 
by any detection method
6 938 1.77 (1.20–2.62) S (P = 0.004)
Positive IIF 4 464 1.17 (0.75–1.81) NS (P = 0.488)
Dementia 6 1197 2.01 (1.22–3.33) S (P = 0.006)
Stroke 6 1231 1.86 (1.29–2.67) S (P < 0.001)
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via a compromised blood–brain barrier, that cross react 
with the skin have been speculated as a possible cause 
[20]. Neurological diseases may be responsible for the 
poor prognosis of some patients with BP because of their 
altered general condition. However, patients with neu-
rodegenerative disorders are known to have increased 
blood–brain barrier permeability that may facilitate the 
generation and crossing of BP autoantibodies into the 
periphery, worsening skin damage, and clinical outcome 
[8]. A recent study revealed that in a group of patients 
with Alzheimer’s disease but no bullous pemphigoid, 
their sera contained much higher level of BP180 autoan-
tibody than neurologically healthy controls. Further-
more, increased levels of the autoantibody were associ-
ated with more severe dementia [19]. Thus, it remains 
unclear whether neurological disease itself could increase 
the mortality risk, or the increased risk is conferred by 
functional impairment and decreased autonomy result-
ing from neurological disease. Future prospective studies 
should assess patient’s functional status at initial presen-
tation and employ a multivariate analysis to answer this 
question.
Meta-analysis of some other prognostic factors was not 
conducted, because the data were too sparse or heteroge-
neous to combine analytically. Poor general condition, 
low karnofsky scale, or being bedridden has been repeat-
edly reported to be associated with unfavorable outcome 
[3, 15, 32], with the exception of one study conducted 
by Lee et al. [21], which did not find a significant asso-
ciation between karnofsky scale and BP mortality after 
multivariate analysis. Low serum albumin level and high 
erythrocyte sedimentation rate (ESR) were found to be 
associated with elevated mortality risk in BP [22, 30]. 
High ESR may be a surrogate marker for more severe 
inflammatory status and more severe disease. Serum 
albumin level is related to patient’s nutritional condition, 
or underlying diseases, or extensive cutaneous erosions. 
However, these two factors are easily influenced by vari-
ous factors, such as other acute and chronic illnesses, so 
they do not represent intrinsic biological variables of bul-
lous pemphigoid.
Steroid is the first line therapy in both localized and gen-
eralized BP [17]. High dosage of systemic corticosteroid or 
immunosuppressive agents correlates with higher mortal-
ity and increased side effects especially in patients at risk, 
as early deaths in BP patients are mainly of infectious or 
cardiovascular origin [16]. However, we were not in an 
optimal situation to validly investigate this issue, because 
(1) treatment modalities had not been predetermined and 
controlled in most studies in our analysis; (2) the average 
dosage of steroid used in different studies varied greatly; 
(3) dosage and route of administration were largely deter-
mined by patients’ disease status; and (4) patients were 
often administered a combination of systemic steroid, topi-
cal steroid, and adjunctive immunomodulators.
Potential limitations need to be considered when inter-
preting the results of our meta-analysis. First, since most 
included studies were retrospective and conducted in refer-
ral centers, a potential unidentified confounding, informa-
tion, and selection bias may exist, causing us to interpret 
our results with caution. Second, the follow-up time var-
ied from 1 to 5 years among studies, which may influence 
the comparability of the results between component stud-
ies. Third, pooled results for some factors, such as mucosal 
involvement and positive IIF, were based on a limited num-
ber of studies. Therefore, we cannot rule out the possibil-
ity that insufficient statistical power is present. Finally, we 
could not evaluate all of the predictive factors for BP mor-
tality in this meta-analysis.
Conclusion
Taken together, our results indicated that BP patients with 
older age, circulating BP autoantibodies, dementia, and 
stroke are at greater risk of mortality. Given that this con-
clusion was made using pooled data derived from mul-
tiple studies, such information has value for the purposes 
of patient education and prognosticating risk during the 
treatment process. Prognostic studies based on prospective 
design have the advantage of ruling out confounding effect, 
such as treatment regimen. More rigorously designed pro-
spective studies with long-term follow-up duration are still 
required for future supplements and updates.
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